LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 46 filers reported holding LYRA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $185,654 | -7.1% | 47,482 | -2.3% | 0.00% | – |
| Q2 2023 | $199,804 | +140.2% | 48,614 | +17.5% | 0.00% | – |
| Q1 2023 | $83,174 | -34.0% | 41,380 | +3.2% | 0.00% | – |
| Q4 2022 | $125,959 | -35.7% | 40,114 | +2.8% | 0.00% | – |
| Q3 2022 | $196,000 | -16.6% | 39,015 | -6.2% | 0.00% | – |
| Q2 2022 | $235,000 | +205.2% | 41,582 | +118.8% | 0.00% | – |
| Q1 2022 | $77,000 | -3.8% | 19,006 | +4.0% | 0.00% | – |
| Q4 2021 | $80,000 | -50.9% | 18,273 | +2.6% | 0.00% | – |
| Q3 2021 | $163,000 | +1.2% | 17,818 | -11.4% | 0.00% | – |
| Q2 2021 | $161,000 | -96.0% | 20,120 | -94.2% | 0.00% | – |
| Q1 2021 | $4,038,000 | +34.1% | 348,394 | +31.9% | 0.00% | – |
| Q4 2020 | $3,012,000 | +30.0% | 264,165 | +27.4% | 0.00% | – |
| Q3 2020 | $2,317,000 | -0.5% | 207,326 | +1.0% | 0.00% | – |
| Q2 2020 | $2,328,000 | – | 205,260 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 1,100,852 | $12,550,000 | 16.38% |
| Soleus Capital Management, L.P. | 456,138 | $5,199,000 | 0.69% |
| Ikarian Capital, LLC | 815,364 | $9,295,000 | 0.41% |
| Perceptive Advisors | 3,222,561 | $36,737,000 | 0.39% |
| Affinity Asset Advisors, LLC | 50,000 | $570,000 | 0.30% |
| RA Capital Management | 815,849 | $9,301,000 | 0.13% |
| ArrowMark Colorado Holdings LLC | 775,888 | $8,845,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 87,353 | $996,000 | 0.04% |
| Altium Capital Management LP | 5,218 | $59,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 49,000 | $559,000 | 0.01% |